Observed Signal · May 1, 2026 · Funding · Source: techcrunch · Impact: 2/5 · Sentiment: Positive
Musely Gets $360M Non‑Dilutive Funding from General Catalyst
Musely, a direct-to-consumer telemedicine platform specializing in compounded treatments for skin, hair and menopause care, has secured over $360 million in non-dilutive capital from General Catalyst’s Customer Value Fund (CVF). The financing is structured like a revenue-share alternative — not equity and not a traditional interest-bearing loan — allowing Musely to fund sales, marketing and customer-acquisition efforts without diluting ownership. Musely, founded in 2014 and pivoted to prescription skincare in 2019, says it has been cash-flow positive for years, is growing revenue roughly 50% year-over-year, and has served over 1.2 million patients. Musely previously raised $20 million in 2014 and had not taken equity since. CVF’s portfolio includes companies such as Grammarly, Lemonade and Ro.
Significant non-dilutive financing for a cash-flow-positive DTC healthcare brand that can accelerate customer acquisition and signals investor interest in revenue-based financing, but not industry-shifting.
Track General Catalyst Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your free Explorer workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Musely secured over $360 million in non-dilutive capital from General Catalyst’s Customer Value Fund (CVF).
- The financing is structured similarly to a capped revenue-share agreement rather than an equity stake or a standard interest-bearing loan.
- Musely is a DTC telemedicine platform focused on compounded treatments for skin, hair and menopause care; it was founded in 2014 and pivoted to prescription skincare in 2019.
- Musely reports being cash-flow positive, growing revenue ~50% year-over-year, and having served over 1.2 million patients.
- Prior to this deal, Musely had raised $20 million in 2014 from DCM and other investors and had not taken equity capital since.
Connected Companies & Entities
4 Entities mappedOntology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
H1 raises $40M led by CVS Health Ventures
H1, a nine-year-old healthcare data platform, raised $40 million in a round led by CVS Health Ventures. CEO and co-founder Ariel Katz said H1 — which licenses detailed physician data to pharma companies, hospital systems and insurers — turned cash-flow and EBITDA profitable last year and is forecasting over 40% growth this year. Katz argued that being a data-first provider makes H1 less vulnerable to AI replacement and could make it a supplier to model makers. H1 was last valued at $750 million after a $100 million round in November 2021 led by Altimeter Capital, and the company has grown through acquisitions of smaller competitors and complementary businesses.
Nectar Social raises $30M Series A led by Menlo
Nectar Social, an AI-powered marketing operating system, raised $30 million in a Series A round led by Menlo Ventures and its Anthology Fund (created alongside Anthropic). The company, which exited stealth in 2025, uses autonomous AI agents to manage social activity, moderation, creator workflows, competitive intelligence and commerce conversations across platforms. Nectar has data partnerships with Meta and Reddit to aggregate platform data for brands. Founded by sisters Misbah and Farah Uraizee (both ex-Meta), the startup says the funding will be used to expand hiring across applied AI, engineering and go-to-market. Clients cited include Liquid Death, Figma and e.l.f Beauty; other investors in the round include Kinship Ventures, GV and True Ventures.
Simile Raises $200M Series B at $2B Valuation
Simile, a startup that builds synthetic/simulated users for marketing and product research, raised $200 million in a Series B at a $2 billion valuation. The round, announced July 30, 2026, was led by Greenoaks with participation from Index Ventures, Hanabi, Bain Capital Ventures, A*, Factory, Definition and CVS Health Ventures. The raise comes five months after Simile's $100 million Series A led by Index. Simile was founded by Joon Sung Park and counts CVS among its customers. The company positions its technology as a way to simulate user behavior for research and product testing, attracting growing VC interest in the synthetic-user market.
Track Real-Time Market Signals & Shifts
Set up custom watchlists to receive automated, evidence-grounded executive digests whenever material signals or shifts occur across your tracked landscape.